Accumulator adjustment programs can lead to increased use of copay assistance and increase the risk of patient discontinuation

Increased Copay Assistance Altered Patient Behavior Reduction in Drug Utilization Spend After exhausting the manufacturer's **Patients stay in their deductible** assistance the patient can face with Overall drug utilization could **Accumulator** phase longer, or take longer to higher out-of-pocket costs decrease, reducing payer spending; reach the annual out-of-pocket the proliferation of these programs More patients will likely discontinue **limit**, meaning they will face higher indicate that they are effective at therapy earlier due to the higher out-ofout-of-pocket costs and use more copay reducing drug utilization pocket costs after a copay card's benefit is assistance exhausted



IQVIA tracked patients longitudinally to understand the surprise cost sharing patients face after hitting the co-pay card cap




Facing consistent costs, Patient A is not included in co-pay surprise analyses as their costs never increase unexpectedly

Patient B sees a cost increase not tied to an annual plan reset that is likely due to an accumulator adjuster exhausting the co-pay card cap, and is included in co-pay surprise analysis



25% - 36% of commercially insured patients that face a copay surprise of \$1,500 or greater are likely to discontinue therapy

Patients in plans with accumulator adjustment programs will likely face a copay surprise of \$1,500 or greater after reaching the copay card cap, as they will not have made progress towards meeting their deductible or annual out-of-pocket maximum



^{* 2020} data through April Source: Healthcare.gov; IQVIA LAAD data; IQVIA US Market Access Strategy Consulting analysis